FindTrial
Sign In

Rituxan injection specific drug use-results survey

Rituxan injection specific drug use-results survey - Rituxan injection specific drug use-results survey

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000011549
Enrollment
Unknown
Registered
2013-09-01
Start date
2013-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wegener&#39

Interventions

None listed

Sponsors

Zenyaku Kogyo Co., Ltd.
Lead Sponsor
Chugai Pharmaceutical Co., Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who have received rituximab for WG and MPA.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
1. Safety (infusion-related reactions and infections) 2. Efficacy—

Countries

Japan

Contacts

Public ContactTakashi Ando

Zenyaku Kogyo Co., Ltd. Pharmacovigilance Department

Takashi_Ando@mail.zenyaku.co.jp03-3946-1136

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026